Daniel Vitt, Immunic CEO
June 3, 2022 11:01 AM EDT
R&D

Im­mu­nic shares cut in half as biotech dumps ul­cer­a­tive col­i­tis af­ter PhII fail

Paul Schloesser

Associate Editor

Fails can be­come cost­ly, so in an ef­fort to stem loss­es, Im­mu­nic and CEO Daniel Vitt have de­cid­ed to throw in the tow­el on ul­cer­a­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times